Reuters logo
BRIEF-Novartis says Phase III study demonstrates adjuvant Tafinlar® + Mekinist reduced the risk of disease recurrence by 53 pct in patients with resected BRAF V600 mutation-positive melanoma
September 10, 2017 / 10:12 PM / 3 months ago

BRIEF-Novartis says Phase III study demonstrates adjuvant Tafinlar® + Mekinist reduced the risk of disease recurrence by 53 pct in patients with resected BRAF V600 mutation-positive melanoma

Sept 10 (Reuters) - Novartis Ag

* Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma

* Novartis - findings from COMBI-AD study, which met primary endpoint, found 53% reduction in risk of death or recurrence in patients Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below